Open house Arzneimittelrabattverträge Rituximab, ATC L01FA01

The AOK Bayern - Die Gesundheitskasse in Germany from Europe region has released this tender for This is not an open procedure, but rather an open-house model! The form for the open procedure is only used because no form exists for the open-house model. Contracts concluded under the open-house model are not subject to public procurement law due to the lack of a selection process. Using this form does not imply any obligation to comply with public procurement regulations. AOK Bayern intends to conclude non-exclusive discount agreements for the active ingredient rituximab, ATC L01FA01, with all interested pharmaceutical companies in accordance with Section 130a Paragraph 8 of the German Social Code, Book V (SGB V). AOK Bayern offers all interested pharmaceutical companies that meet the eligibility requirements listed below the opportunity to conclude identical and non-negotiable discount agreements. The earliest possible start date for the contracts is December 1, 2026, and all contracts will end on November 30, 2028. A contract can be concluded at any time during this term, but no later than October 3, 2028. Contracts can be terminated with one months notice to the end of the month. Upon the entry into force of a nationwide or state-specific discount agreement for pharmaceuticals containing the active ingredient in question, concluded via an open procedure, the open-house agreements will automatically cease to be valid for the corresponding term. A contract will be concluded with all interested pharmaceutical companies that demonstrate their suitability by submitting a completed and signed self-declaration of reliability. The pharmaceutical company must submit the completed and signed contract (the signatorys authority to represent the company must be evident from the commercial register extract; otherwise, a power of attorney must be provided) along with the completed and signed appendix "Definition of the Pharmaceuticals Subject to the Contract" and the completed and signed self-declaration of reliability. The documents can be submitted EITHER in handwritten form with a signature by hand OR ELECTRONICALLY with a qualified electronic signature. Handwritten documents must be submitted in duplicate to the following address: AOK Bayern - Die Gesundheitskasse, Fachbereich Vertragsmanagement AZMV open-house Rabattverträge, Carl-Wery-Str. 28, 81739 München. Electronic documents with a qualified electronic signature must be submitted via the communication section of the procurement portal www.dtvp.de. If complete and correct documents are received by the 3rd of each month, the contract will commence on the first day of the following month; otherwise, it will commence on the first day of the month after that. For handwritten documents, a scanned copy of the complete, filled-out, and signed documents must be sent in advance to the email address amv_bay_Rabattvertrag@by.aok.Applications must be submitted online or via the communication section of the procurement portal www.dtvp.de to meet the deadline, provided the complete and correct original documents in paper form are received by AOK Bayern, Procurement Office, by the 10th of the month. Please refer to the instructions for completing the documents, which are available at www.dtvp.de with the tender documents. Interested pharmaceutical companies can request access to the tender documents in the project room for the Open House procedure on the portal www.dtvp.de. A link to the portal is included in this announcement. Only pharmaceutical companies are eligible as potential contracting partners. The documents for the Open House procedure will only be made available to pharmaceutical companies as potential contracting partners and must be treated as strictly confidential. By requesting access, companies confirm their commitment to the confidentiality of the documents. with tender notice no. 714205-2026 published on 15 Oct 2026. The tender is due to expire on 03 Oct 2028. This tender is sourced from TED Europa and is eligible for suppliers interested in Pharmaceutical products, General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents, Antineoplastic and immunomodulating agents, Antineoplastic agents. Interested bidders can obtain further information including complete bid documents or ways to participate by registering on Tender Impulse and referencing via Tender Impulse ID 15571955.